AI주식인사이트AI Stock Insight
C

셀루메드

049180KOSDAQ기초 의약물질 제조업

45.0 / 100

Reference Date: 2026-07-24

Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure7.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellumed operates in various sectors including medical devices, biologics, and cosmeceuticals, focusing on tissue engineering-based medical devices and growth factor manufacturing. The company is expanding into mRNA vaccine production enzyme development, secondary battery, and electric bicycle businesses, aiming for overseas market entry. It also diversifies through subsidiaries engaged in environmental engineering and real estate development.

Number of Employees

83people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
10.01Industry Average 1.260.0Point

7.9x industry avg (risky)

ROE
-25.02Industry Average -6.033.5Point

4.1x industry avg (excellent)

Debt Ratio
23.59Industry Average 6.620.0Point

3.6x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲21.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲29.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -106.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 1,009Won52-week high 2,57052-week low 570
1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1
  • Neutral[기재정정]사업보고서 (2025.12)2026-07-10
  • Negative[기재정정]투자판단관련주요경영사항 (집행판결 청구소송 합의 변경의 건)2026-06-30
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-06-25